Skip to main content
HERAMED LIMITED logo

HERAMED LIMITED — Investor Relations & Filings

Ticker · HMD ISIN · AU0000028367 LEI · 875500WOB41XBFTTJ477 ASX Manufacturing
Open in API
Filings indexed 524 across all filing types
Latest filing 2023-01-15 Regulatory Filings
Country AU Australia
Listing ASX HMD

About HERAMED LIMITED

https://hera-med.com/

HeraMED Limited is a medical technology company specializing in the development and commercialization of digital health solutions for maternity care. The company focuses on providing remote monitoring tools that bridge the gap between expectant mothers and healthcare providers. Its flagship product, HeraBEAT, is a medical-grade, smartphone-based fetal heart rate monitor designed for home use, allowing for accurate and reliable monitoring of fetal well-being. This hardware is integrated into the HeraCARE platform, a comprehensive digital maternity care solution that enables remote data management, personalized care plans, and seamless communication between patients and clinicians. By leveraging cloud-based technology and advanced sensors, the company aims to enhance prenatal care, improve clinical outcomes, and offer peace of mind through continuous, data-driven insights throughout the pregnancy journey.

Recent filings

Filing Released Lang Actions
Correction - Notice of General Meeting 1 page 98.8K
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 16 January 2023, correcting a typographical error in the Notice of General Meeting's Explanatory Memorandum. It references the Annual General Meeting released on 9 September 2022 but does not contain the AGM materials itself. The document is short (2203 characters) and serves as a correction notice rather than the AGM information or the Notice itself. Therefore, it is best classified as a Regulatory Filing (RNS), which is the fallback for miscellaneous announcements that do not fit other categories.
2023-01-15 English
Notice of General Meeting 7 pages 919.2KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled 'NOTICE OF GENERAL MEETING' and includes detailed information about the time, place, voting eligibility, proxy voting instructions, and the business of the meeting, including a resolution to amend terms and conditions of options. It contains an explanatory statement and proxy form instructions, which are typical components of a notice sent to shareholders to inform them about an upcoming general meeting and to solicit their votes. There is no financial data or report content, but rather procedural and voting information related to a shareholder meeting. This matches the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings.
2022-12-28 English
Ramsay Affiliated Melbourne Mothers Practice Adopts HeraCARE 3 pages 184.9KB
Capital/Financing Update Classification · 90% confidence The document is an ASX announcement dated 23 November 2022 from HeraMED Limited. It details a new agreement with a private obstetrician practice to adopt HeraCARE, a maternity care platform, including the purchase of licenses and devices. The content focuses on the commercial launch, project phases, and key performance indicators, with no financial statements or detailed financial performance data. It is a corporate announcement about a business development and partnership rather than a financial report or regulatory filing. The document length is 7324 characters, which is substantial but the content is clearly an announcement of a new agreement and project launch. Therefore, it fits best under Capital/Financing Update (CAP) as it relates to a commercial agreement and business expansion involving product licenses and sales, rather than other categories like Annual Report, Earnings Release, or Regulatory Filings.
2022-11-22 English
JHCs Clinical Trial Published in Nature Portfolio 2 pages 151.1KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 8 November 2022 about the publication of a clinical trial peer-reviewed and published in Nature Portfolio. It discusses the clinical study results and provides a link to the full publication on the company's website. The document is short (3597 characters) and serves as an announcement of the publication rather than the full clinical trial report or detailed financial data. There is no indication of financial results, management discussion, or regulatory filings. It is not a report itself but an announcement about a significant milestone publication. Therefore, it fits best as a Regulatory Filing (RNS) since it is a general regulatory announcement that does not fit other specific categories.
2022-11-07 English
Quarterly Activities & Cashflow Report 8 pages 358.2KB
Interim / Quarterly Report Classification · 100% confidence The document is an ASX announcement dated 28 October 2022 titled 'Quarterly Activities & Cashflow Report' for HeraMED Limited. It includes detailed operational updates, commercial progress, board appointment, and a financial overview including a cash flow statement for the quarter ended 30 September 2022. The presence of the Appendix 4C cash flow report, which is a regulatory requirement for quarterly reporting by ASX-listed entities, confirms this is a quarterly report containing substantive financial data and analysis for a period shorter than a full fiscal year. The document is approximately 15,000 characters long, indicating it is a full report rather than a brief announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q3 2022
2022-10-27 English
Application for quotation of securities - HMD 6 pages 27.7KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX by Heramed Limited. It details the number and type of securities to be quoted, issue dates, distribution schedules, and issued capital following quotation. The document is a formal announcement related to the listing or quotation of securities rather than a financial report, earnings release, or management discussion. It does not contain financial statements or management commentary but is focused on the capital market transaction of securities quotation. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2022-10-24 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.